The global cell and gene therapy (CGT) pipeline is advancing at an unprecedented pace, transitioning rapidly from early discovery to late-stage clinical development and commercialization. This session will provide an in-depth overview of emerging therapeutic areas, with a particular focus on rare and orphan diseases where CGTs are demonstrating transformative potential. Discussions will highlight key molecules across clinical phases, strategic partnerships, and licensing activities shaping the global CGT landscape. In addition, experts will examine technology trends, innovation clusters, and intellectual property developments, offering strategic insights into how science, business, and regulation intersect to drive next-generation therapy pipelines.